Actinium Pharmaceuticals for Global Partnership & Investment at the Sachs 19th Annual Biotech Forum in Europe

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM)(‘ Actinium’) announced today that it will be presenting Global Partnership & Investment at the Sachs 19th Annual Biotech in Europe Forum. The forum will take place on September 25-26, 2019 at the Basel Congress Center in Basel, Switzerland. More than 700 delegates from around the globe are expected to attend the event.
For one-on-one conferences with meeting participants, members of Actinium’s Executive Team will be accessible. If you are interested in scheduling a conference with Actinium, please contact David Gould, MD, Senior Vice President, Corporate Development and Affairs by email at dgould@actiniumpharma.com.
About the Sachs 19th Annual Biotech in Europe Forum

For those interested in investing and partnering in the biotech and life science sector, the 19th Annual Biotech in Europe Forum is acknowledged as a major global level. The event brings together a cross-section of early-stage / pre-IPO, late-stage and government businesses with leading investors, analysts, cash managers and executives in pharmaceutical licensing.

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a biopharmaceutical clinical-stage firm focused on enhancing patient access and cellular therapy results such as BMT or Bone Marrow Transplant and CAR-T with its proprietary ARC or Antibody Radiation-Conjugate targeted conditioning technology. Actinium is also creating its proprietary technology platform AWE or Antibody Warhead Enabling, which uses radioisotopes including iodine-131 and extremely distinguished actinium-225 combined with antibodies to target a range of antigens expressed in hematological and solid tumor signs for this patient population, BMT is the only curative therapy alternative and there is presently no standard of care. Actimab-MDS is its second pivotal program for targeted conditioning that will study the ARC comprised of the anti-CD33 monoclonal antibody lintuzumab linked to the radioisotope actinium-225 in patients with high-risk MDS in combination with RIC or Reduced Intensity Conditioning.
Actinium also has numerous continuing clinical trials to use its CD33 ARC in conjunction with other therapeutic methods such as chemotherapy, targeted agents, or immunotherapy in the start-up stage or scheduling phase. It has launched several combination tests, including a double combination test with its CD33 ARC and a BCL-2 inhibitor, a triplet for patients with relapsed or refractory AML.

,